Matsutani N, Yokozaki H, Tahara E, Tahara H, Kuniyasu H, Haruma K, Chayama K, Yasui W, Tahara E
First Department of Pathology, Hiroshima University School of Medicine, Hiroshima 734-8511, Japan.
Int J Oncol. 2001 Sep;19(3):507-12.
Telomeric repeat binding factor 1 (TRF1) and 2 (TRF2) may play key roles in the maintenance of telomere function. TRF1 negatively regulates telomere elongation, while TRF2 protects the chromosome ends by inhibiting end-to-end fusions. We examined the expression of TRF1 and TRF2 in 20 gastric carcinomas by reverse transcription polymerase chain reaction and then analyzed the relation with telomerase activity and other telomerase components such as human telomerase reverse transcriptase (TERT), human telomerase RNA component (hTR), human telomerase-associated protein (TEP1) and TRF1-interacting, ankyrin-related ADP-ribose polymerase (tankyrase) as well as TRF1-interacting nuclear protein 2 (TIN2). Of 20 gastric carcinomas examined, 10 (50%) and 12 (60%) expressed TRF1 and TRF2 at higher levels than did non-neoplastic mucosa, respectively. No obvious correlation was observed between TRF1 expression and telomerase activity or expression of TERT, hTR and TEP1. Carcinomas with high TRF1 expression expressed significantly higher levels of tankyrase and TIN2 than did those with low TRF2 expression (p<0.05). The telomerase activities and the levels of TERT, hTR and TEP1 showed tendency to be lower in tumors expressing TRF1 at low levels, although it was not significant. On the other hand, carcinomas with short telomere length (shorter than 2 Kbp) expressed significantly stronger telomerase activities and higher TRF1 expression (p<0.05) and tended to express TRF2 and TIN2 at higher levels than those with long telomere length. The results suggest that gastric carcinomas with short telomeres need high levels of telomerase activity and large quantity of TRFs and TIN2, whereas those with long telomeres do not require high levels of telomerase activity and telomere associated proteins.
端粒重复结合因子1(TRF1)和2(TRF2)可能在端粒功能的维持中发挥关键作用。TRF1负向调节端粒延长,而TRF2通过抑制端端融合来保护染色体末端。我们通过逆转录聚合酶链反应检测了20例胃癌中TRF1和TRF2的表达,然后分析了其与端粒酶活性以及其他端粒酶组分如人端粒酶逆转录酶(TERT)、人端粒酶RNA组分(hTR)、人端粒酶相关蛋白(TEP1)、TRF1相互作用的锚蛋白相关ADP核糖聚合酶(端粒多聚腺苷二磷酸核糖基聚合酶)以及TRF1相互作用核蛋白2(TIN2)之间的关系。在检测的20例胃癌中,分别有10例(50%)和12例(60%)的TRF1和TRF2表达水平高于非肿瘤黏膜。未观察到TRF1表达与端粒酶活性或TERT、hTR和TEP1表达之间存在明显相关性。TRF1高表达的癌组织中端粒多聚腺苷二磷酸核糖基聚合酶和TIN2的表达水平显著高于TRF2低表达的癌组织(p<0.05)。端粒酶活性以及TERT、hTR和TEP1的水平在TRF1低表达的肿瘤中呈降低趋势,尽管不显著。另一方面,端粒长度较短(短于2 Kbp)的癌组织端粒酶活性显著更强,TRF1表达更高(p<0.05),并且与端粒长度较长的癌组织相比,TRF2和TIN2的表达水平有升高趋势。结果表明,端粒短的胃癌需要高水平的端粒酶活性以及大量的TRF和TIN2,而端粒长的胃癌则不需要高水平的端粒酶活性和端粒相关蛋白。